Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icomidocholic acid - Galmed Pharmaceuticals

Next Previous
Drug Profile

Icomidocholic acid - Galmed Pharmaceuticals

Alternative Names: Arachidyl amido cholanoic acid; Arachidyl amido cholanoic acid - Galmed Pharmaceuticals; Aramchol; Aramchol - Galmed Pharmaceuticals; Aramchol meglumine - Galmed Pharmaceuticals

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galmed Medical Research
  • Developer Galmed Medical Research; Galmed Pharmaceuticals; University of California, San Diego
  • Class Anti-inflammatories; Antifibrotics; Bile acids and salts; Cholic acids; Drug conjugates; Eicosanoic acids; Eicosanoids; Fatty acids; Gallstone therapies; Hepatoprotectants; Small molecules
  • Mechanism of Action Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Lipodystrophy; Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase III Fibrosis; Non-alcoholic steatohepatitis
  • Phase II Cholelithiasis; Lipodystrophy; Non-alcoholic fatty liver disease
  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 15 Mar 2024 Galmed Pharmaceuticals has patent protection for icomidocholic acid in France, Germany, Italy, the Netherlands and the United Kingdom
  • 15 Mar 2024 Galmed Pharmaceuticals has patents pending for icomidocholic acid in USA
  • 20 Nov 2023 Galmed Pharmaceuticals announces intention to submit IND to US FDA for Primary Sclerosing Cholangitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top